Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Clinical Nuclear Medicine|December 30, 2025
Tubular MAG3 Extraction Rate is a Predictor of Short-Term and Long-Term Outcome After Kidney Transplantation: A Prospective Observational StudyAnna Buckenmayer, Rudolf Werner, Daniel Groener, et al.
Thyroid : Official Journal of the American Thyroid Association|April 13, 2026
Real-World Efficacy and Safety of Lenvatinib and Sorafenib in Thyroid Cancer: A Retrospective, Propensity-Score-Matched StudyMax Kappenstein, Viktoria Florentine Koehler, Nadia Ninosu, et al.
Cancers|September 28, 2023
Intermittent Radioligand Therapy with <sup>177</sup>Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate CancerNicolai Mader, Christina Schoeler, Niloufar Pezeshkpour, et al.
Cancers|January 21, 2023
Baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT before [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable LesionsDaniel Groener, Sina Schneider, Justus Baumgarten, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 26, 2023
Extended therapy with [<sup>177</sup>Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancerNicolai Mader, Christina Nguyen Ngoc, Bilge Kirkgöze, et al.
Cancers|August 27, 2021
Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow InvolvementDaniel Groener, Justus Baumgarten, Sebastian Haefele, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 7, 2025
Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patientsMike Wenzel, Lena Theissen, Daniel Groener, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2025
Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapyMike Wenzel, Benedikt Hoeh, Carolin Siech, et al.
Cancers|February 15, 2022
Safety and Efficacy of <sup>177</sup>Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing <sup>223</sup>Radium-DichlorideJustus Baumgarten, Daniel Groener, Christina Nguyen Ngoc, et al.
Theranostics|March 14, 2025
Cancer-control outcomes with [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patientsMike Wenzel, Carolin Siech, Cristina Cano Garcia, et al.
Pageof 3